Larry A. Wheeler

Larry Wheeler is the Chief Technical Officer for Perceive Biotherapeutics and Adjunct Research Professor, Moran Eye Center, Department of Ophthalmology, University of Utah. Prior to Perceive Biotherapeutics he was Senior Vice-President of Biological Sciences, Discovery Research at Allergan, Inc for over 30 years, where he worked collaboratively to identify and nominate compounds for clinical development such as Alphagan formulations, brimonidine SR, Lumigan, Durysta, Ozurdex, Restasis, Zorac, abicipar Pegol, senrebotase and onabotulinumtoxinA indications. He has authored book chapters and over 110 papers in peer-reviewed journals and received over 60 patents in the areas of neuroprotection, alpha-2 receptors, NMDA antagonists, age related macular degeneration, dry eye and sustained drug delivery.

Prior to joining Allergan, Larry received a BS from the University of Redlands and an M.S. and Ph.D. from Loma Linda Medical School. He did Postdoctoral research in the Department of Pharmacology at Harvard Medical School and served as Assistant Professor in the Department of Pharmacology at the University of California at Los Angeles and Research Scientist at the Wadsworth VA Hospital.